In the multicentre, double-blind, randomised, placebo-controlled, phase 3 KEYNOTE-189 study done at 126 cancer centres in 16 countries, eligible patients aged 18 years or older with histologically or cytologically confirmed metastatic non-squamous non-small-cell lung cancer without sensitising EGFR or ALK alterations, measurable disease as per Response Evaluation Criteria in Solid Tumors (version 1.1), and an Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled. We aimed to evaluate prespecified exploratory patient-reported outcomes (PROs) in patients in KEYNOTE-189. Pembrolizumab plus pemetrexed-platinum led to superior overall survival and progression-free survival, and a higher proportion of patients with a confirmed complete or partial response over placebo plus pemetrexed-platinum in the KEYNOTE-189 study. 17 Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.15 Chris O'Brien Lifehouse, Camperdown, NSW, Australia.14 David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.13 Westmead Hospital and University of Sydney, Sydney, NSW, Australia.12 LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.11 Clalit Health Services, Soroka Medical Center, Beer-Sheeva, Israel.9 Sunnybrook Health Sciences Centre, Toronto, ON, Canada.8 Sanford Health, Sioux Falls, SD, USA.7 Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Vienna, Austria.6 Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.5 Centre Intégré de Cancérologie de la Montérégie, Hôpital Charles-Le Moyne, Greenfield Park, QC, Canada.4 Vall d'Hebron University, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.3 Hospital Universitario Central de Asturias, Oviedo, Spain.Electronic address: 2 Department of Medical Oncology 1, University of Michigan, Ann Arbor, MI, USA. 1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |